Evoke Pharma Price to Free Cash Flow Ratio 2012-2025 | EVOK
Historical price to free cash flow ratio values for Evoke Pharma (EVOK) since 2012.
| Evoke Pharma Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-02-27 | 29.90 | 0.00 | |
| 2025-09-30 | 4.97 | $-0.67 | 0.00 |
| 2025-06-30 | 2.60 | $-0.98 | 0.00 |
| 2025-03-31 | 2.75 | $0.15 | 18.26 |
| 2024-12-31 | 4.42 | $-2.87 | 0.00 |
| 2024-09-30 | 4.76 | $-6.98 | 0.00 |
| 2024-06-30 | 6.35 | $-10.19 | 0.00 |
| 2024-03-31 | 7.32 | $-15.42 | 0.00 |
| 2023-12-31 | 12.60 | $-17.87 | 0.00 |
| 2023-09-30 | 16.56 | $-24.40 | 0.00 |
| 2023-06-30 | 19.80 | $-23.99 | 0.00 |
| 2023-03-31 | 22.80 | $-23.94 | 0.00 |
| 2022-12-31 | 32.16 | $-25.19 | 0.00 |
| 2022-09-30 | 22.44 | $-24.14 | 0.00 |
| 2022-06-30 | 38.88 | $-46.80 | 0.00 |
| 2022-03-31 | 71.28 | $-48.73 | 0.00 |
| 2021-12-31 | 79.20 | $-55.29 | 0.00 |
| 2021-09-30 | 187.20 | $-56.21 | 0.00 |
| 2021-06-30 | 197.28 | $-39.41 | 0.00 |
| 2021-03-31 | 263.52 | $-41.99 | 0.00 |
| 2020-12-31 | 371.52 | $-37.48 | 0.00 |
| 2020-09-30 | 675.36 | $-36.79 | 0.00 |
| 2020-06-30 | 509.76 | $-33.14 | 0.00 |
| 2020-03-31 | 167.04 | $-30.51 | 0.00 |
| 2019-12-31 | 233.28 | $-37.24 | 0.00 |
| 2019-09-30 | 123.84 | $-39.94 | 0.00 |
| 2019-06-30 | 90.00 | $-42.42 | 0.00 |
| 2019-03-31 | 216.00 | $-50.14 | 0.00 |
| 2018-12-31 | 357.12 | $-60.58 | 0.00 |
| 2018-09-30 | 429.12 | $-76.06 | 0.00 |
| 2018-06-30 | 360.00 | $-88.85 | 0.00 |
| 2018-03-31 | 299.52 | $-92.38 | 0.00 |
| 2017-12-31 | 325.44 | $-84.02 | 0.00 |
| 2017-09-30 | 480.96 | $-90.93 | 0.00 |
| 2017-06-30 | 368.44 | $-71.51 | 0.00 |
| 2017-03-31 | 446.40 | $-98.27 | 0.00 |
| 2016-12-31 | 290.88 | $-134.39 | 0.00 |
| 2016-09-30 | 325.44 | $-154.37 | 0.00 |
| 2016-06-30 | 986.40 | $-202.96 | 0.00 |
| 2016-03-31 | 732.96 | $-216.59 | 0.00 |
| 2015-12-31 | 475.20 | $-233.21 | 0.00 |
| 2015-09-30 | 419.04 | $-239.43 | 0.00 |
| 2015-06-30 | 753.12 | $-282.05 | 0.00 |
| 2015-03-31 | 1015.20 | $-297.42 | 0.00 |
| 2014-12-31 | 849.60 | $-274.74 | 0.00 |
| 2014-09-30 | 791.93 | $-259.41 | 0.00 |
| 2014-06-30 | 1164.96 | $-306.20 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |